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Abstract
Background: Type I diabetes (TID) is an autoimmune disease resulting from destruction of the
insulin-producing  β-cells by autoreactive T cells. Studies have shown that polymorphisms of
chemokine CXCL12 gene are linked to TID in humans. In non-obese diabetic (NOD) mice, which
are predisposed to develop the disease, reduction of CXCL12 level leads to significant delays in the
onset of diabetes. Despite these initial observations, however, how CXCL12 affects development
of TID has not been fully investigated.
Results: We found that the level of CXCL12 transcript is significantly elevated in the bone marrow
of NOD mice as compared to Balb/c and C57BL/6 mice. Correspondingly, naïve T cells, regulatory
T cells and hematopoietic stem cells (HSC) accumulate in the bone marrow of NOD mice.
Treatment of NOD mice with AMD3100, an antagonist for CXCL12's receptor CXCR4, mobilizes
T cells and HSC from the bone marrow to the periphery, concomitantly inhibits insulitis and delays
the onset of diabetes.
Conclusion: These results suggest that the elevated CXCL12 expression promotes TID in NOD
mice by altering T cell and hematopoietic stem cell trafficking. The findings highlight the potential
usefulness of AMD3100 to treat or prevent TID in humans.
Background
Type I diabetes (TID) is an autoimmune disease, resulting
from destruction of the insulin-producing β-cells in the
islets of Langerhans by autoreactive T cells. The non-obese
diabetic (NOD) mice, which are predisposed to develop
the disease, have served as a model for studying the mech-
anism, pathogenesis and interventions of the human dis-
ease [1,2]. In NOD mice, a unique major
histocompatibility complex (MHC) class II allele (IAg7) in
combination with a defect in the programmed cell death
pathway is thought to permit autoreactive T cells to escape
negative selection in the thymus [3-5]. In the periphery,
additional defects in peripheral tolerance mechanisms
enable activation of the autoreactive T cells [6-8], leading
to the disease development.
Besides development and activation of autoreactive T
cells, factors that regulate T cell trafficking likely contrib-
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ute to the disease development because destruction of β-
cells requires infiltration of autoreactive T cells into the
islets. Chemokines are a group of low molecular weight
proteins and regulate cell trafficking by binding to specific
G-protein-coupled seven-span transmembrane receptors
on target cells. For example, CXCL12, also known as stro-
mal cell derived factor-1 (SDF-1), and its receptor CXCR4
play a critical role in regulating hematopoietic cell traffick-
ing [9]. It is required for fetal liver-derived hematopoietic
stem cells (HSC) to colonize the bone marrow during
embrogenesis and retention/homing of these cells in the
bone marrow in the adult. It also regulates trafficking of
many other cell types that express CXCR4, including lym-
phocytes and cancer stem cells. In humans, polymor-
phisms in CXCL12 gene are linked to TID [10-12]. In
NOD mice, the onset of diabetes is significantly delayed
by reducing the level of CXCL12 either by antibody-medi-
ated neutralization or G-CSF-induced suppression of
CXCL12 transcription [13-16]. Despite these initial obser-
vations, however, how chemokine CXCL12 affects devel-
opment of TID has not been fully investigated.
In this report, we show that expression of chemokine
CXCL12 is elevated in the bone marrow of NOD mice,
resulting in accumulation of both T cells and HSC in the
bone marrow. Treatment of NOD mice with CXCR4
antagonist AMD3100 [17] mobilizes T cells from the
bone marrow to peripheral lymphoid tissues, and signifi-
cantly delays the onset of insulitis and diabetes. Our find-
ings suggest that the elevated CXCL12 expression in the
bone marrow likely promotes TID in NOD mice by alter-
ing T cell trafficking and stem cell mobilization.
Results
Naive T cells accumulate in the bone marrow of NOD mice
Compared to age-matched Balb/c or C57BL/6 mice, predi-
abetic NOD mice (15–16 week-old and no detectable
urine glucose) had a significantly higher percentage of
CD4+ T cells (~3-fold) in the bone marrow (Figure 1A and
data not shown). The increase was even more pronounced
in diabetic NOD mice (23 week-old, urine glucose ≥ 500
mg/dl), reaching up to 15-fold of that in Balb/c mice (Fig-
ure 1A). Correspondingly, the number of CD4 T cells in
the bone marrow of prediabetic NOD mice (0.86 ± 0.38 ×
106) was 3 times higher than that in the Balb/c bone mar-
row (0.29 ± 0.16 × 106), although both bone marrows had
similar number of cells (41.6 ± 11.1 × 106 versus 46.4 ±
13.3 × 106, p < 0.09) (Figure 1B). In diabetic NOD mice,
the percentages of CD4 T cells in the bone marrow
increased with age (Figure 1C) and the increase was corre-
lated with a decrease of CD4 T cell number in the spleen
(Figure 1D). A similar increase in the percentage and
number of CD8 T cells was also observed in the bone mar-
row of NOD mice (Figure 1B and data not shown).
To investigate the role of inflammation or hyperglycemia
in the T cell accumulation in the bone marrow of NOD
mice, we used 4–5 week-old NOD mice, in which insulitis
(inflammation) was minimal. As shown in Figure 1E, the
percentage of CD4 T cells in the bone marrow was still sig-
nificantly higher (1.2 ± 0.3%) than in age-matched Balb/
c mice (0.2 ± 0.03%). Furthermore, in EA16 mice, which
do not develop diabetes because the transgenic expression
of an I-E molecule confers almost complete protection
from insulitis of NOD mice [18], the percentage of CD4 T
cells in the bone marrow was significantly increased as
compared to Balb/c mice (Figure 1F). In addition, most
CD4 T cells in the bone marrow of prediabetic NOD mice
were CD44loCD45RBhiCD25- naïve T cells (Figure 1G).
The proportion of the naïve T cells increased as the NOD
mice became diabetic. Together, these results show that
naïve T cells accumulate in the bone marrow of NOD
mice.
Increased homing leads to T cell accumulation in the bone 
marrow of NOD mice
To determine if T cell accumulation in the bone marrow
of NOD mice was due to proliferation, T cells in the bone
marrow were stained for cycling marker Ki67. No signifi-
cant difference in the percentages of Ki67+proliferating
CD4 T cells was detected in the bone marrow of predia-
betic NOD mice and age-matched Balb/c mice (Figure
2A). As in Balb/c mice, the proliferating CD4 T cells in the
bone marrow of NOD mice were CD44hi effector or mem-
ory T cells.
To investigate the role of recruitment in T cell accumula-
tion in the bone marrow, total T cells were purified from
NOD and Balb/c mice, labeled with CFSE, and transferred
into both NOD and Balb/c mice. Distribution of CFSE-
positive donor CD4 T cells in the recipients was assayed 2
hours following the transfer. No significant difference was
detected in T cell distribution in the lymph nodes between
Balb/c and NOD mice when either NOD or Balb/c T cells
were transferred (Figure 2B right panel), demonstrating
that T cells from Balb/c and NOD mice have equivalent
motility. However, significantly more transferred Balb/c
and NOD T cells were detected in the bone marrow of
NOD than Balb/c mice (Figure 2B left panel). Forty-eight
hours after the transfer, the difference between T cell dis-
tribution in the bone marrow of NOD and Balb/c recipi-
ents was even greater (see Additional file 1). Therefore,
enhanced recruitment likely contributes to the accumula-
tion of naïve T cells in the bone marrow of NOD mice.
Because the enhanced recruitment is restricted to the bone
marrow and independent of the source of the donor T
cells, factors that mediate the preferential homing of naïve
T cells likely reside in the bone marrow of NOD mice.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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Elevated CXCL12 expression promotes T cell recruitment 
to the bone marrow of NOD mice
To identify chemokines that mediate the observed prefer-
ential T cell homing, we compared chemokine transcrip-
tion in the bone marrow between NOD and Balb/c mice
using Mouse Chemokines & Receptors Microarrays. Only
chemokine CXCL12 and CCL19 transcripts were elevated
in the bone marrow of NOD mice as compared to Balb/c
mice (Figure 3A). Quantitative RT-PCR analysis showed
that the CXCL12 transcript was 3–5 fold higher in the
bone marrow of NOD than Balb/c mice (Figure 3B),
whereas the difference in the level of CCL19 transcript was
not confirmed. Consistently, the level of CXCL12 tran-
script was significantly higher in the bone marrow of 4–5
Accumulation of naïve T cells in the bone marrow of NOD mice Figure 1
Accumulation of naïve T cells in the bone marrow of NOD mice. A. Frequency of CD4 T cells in the bone marrow of 
Balb/c, prediabetic and diabetic NOD mice. Cells from bone marrow (BM), spleen (SP) and pooled lymph nodes (LN, including 
cervical, mediastinal, auxiliary, brachial, mesenteric, and inguinal nodes) were stained for CD4, CD8, TCRβ, and PI. CD4 versus 
TCRβ profiles are shown for live cells. The numbers indicate the percentages of CD4+TCR+ cells in the gated regions. p < 
0.001 comparing percentages of CD4 T cells in the bone marrow between Balb/c and NOD mice. B. The average number of 
CD4 (open bar) and CD8 (solid bar) T cells in the BM, LN and SP of Balb/c (n = 22), prediabetic (n = 19) and diabetic (n = 16) 
NOD mice. p < 0.01 comparing CD4 or CD8 T cells in the bone marrow between Balb/c and prediabetic or diabetic NOD 
mice. C. Increase of percentages of CD4 T cells with age in the bone marrow of diabetic NOD mice. The r2 value is 0.76. D. 
Inverse correlation between percentage of CD4 T cells in the bone marrow and CD4 T cell number in the spleen of the same 
diabetic NOD mice. The r2 value is -0.69. Data presented in C and D are from the same group of mice. One dot represents 
one mouse. E. Comparison of percentages of CD4 T cells in the bone marrow of 4–5 week old BLAB/c (n = 6) and NOD (n = 
8) mice. p < 0.001. F. Comparison of percentages of CD4 T cells in the bone marrow of 6–9 week old Balb/c (n = 5), EA16 (n 
= 3) and NOD (n = 8) mice. p < 0.001 comparing Balb/c to NOD (or EA16) mice. G. Phenotype of bone marrow T cells. Bone 
marrow cells were stained for TCR, CD4, CD25 plus CD45RB, or for TCR, CD4, CD44 and CD45RB. Representative plots 
from at least four independent experiments are shown, gating on CD4+TCR+ cells.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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week-old NOD mice and EA16 mice than their respective
age-matched controls (Figure 3C and 3D). In addition,
majority of CD4 T cells in the spleen, lymph nodes, and
bone marrow of NOD mice that expressed CXCR4 were
CD45RB+ naïve T cells (Figure 3E), consistent with their
accumulation in the bone marrow. Although only a few
percentages of CD4 T cells stained positive for surface
CXCR4, all CD4 T cells from both NOD and C57BL/6
mice were positive for intracellular staining of CXCR4
(data not shown).
AMD3100 is a low molecular weight antagonist of CXCR4
[17]. If interaction of CXCL12 with CXCR4 is critical for
the observed T cell accumulation, treatment of NOD mice
with AMD3100 should inhibit T cell accumulation in the
bone marrow. Thus, prediabetic NOD mice were given
AMD3100 (5 mg/kg) daily for 8 days and the distribution
and phenotype of T cells in their bone marrow were
assayed. AMD3100 treatment significantly reduced the
proportion of both CD4 and CD8 T cells in the bone mar-
row of the prediabetic NOD mice as compared to predia-
betic NOD mice that were given PBS (Figure 4A). In
particular, the proportion of CD4 T cells with the naïve
phenotype (CD45RBhi CD44lo) was preferentially reduced
in the AMD3100 treated NOD mice (Figure 4B). Together
with CXCL12's known function in regulating T cell migra-
tion [19], these results demonstrate that the elevated
CXCL12 expression results in the accumulation of naïve T
cells in the bone marrow of NOD mice.
Elevated CXCL12 expression promotes recruitment/
retention of regulatory T cells (Tregs) and hematopoietic 
stem cells in the bone marrow
The elevated CXCL12 expression is expected to promote
recruitment or retention of other cell types/subsets that
express CXCR4 in the bone marrow of NOD mice.
Although no significant difference in percentage or
number of NKT cells, dendritic cells or B cells was detected
in the bone marrow between NOD and Balb/c mice (data
not shown) nor any change in distribution of these cell
types in NOD mice following AMD3100 treatment (see
Additional file 2 and data not shown), the numbers of
Foxp3+CD4+ Tregs were consistently higher in the bone
marrow of prediabetic NOD mice than Balb/c mice (Fig-
ure 5A). A lower percentage of CD4 T cells that are Tregs
in the bone marrow of NOD mice as compared to Balb/c
mice likely reflects the greater accumulation of naïve CD4
T cells than Tregs in the NOD bone marrow. To unequiv-
ocally determine the involvement of CXCL12-CXCR4
interaction in regulating Treg trafficking, we used mice in
which CXCR4 expression was specifically inactivated in T
cells via Cre-mediated recombination [20]. In the absence
of CXCR4, the numbers of Treg in the bone marrow was
decreased significantly whereas the number of Treg in the
spleen was increased as compared to littermate wildtype
mice (Figure 5B). Thus, Treg trafficking into the bone mar-
row is partly regulated by CXCL12.
CXCL12 plays a critical role in retention of HSC in the
bone marrow of adult mice [9,21]. As expected, the
number of Lin-Sca1+c-Kit+ HSC was significantly higher in
the bone marrow of prediabetic NOD mice than in age-
matched Balb/c mice (Figure 5C). Following AMD3100
treatment for 8 days, the number of HSC in the bone mar-
row of NOD mice was significantly reduced.
T cell accumulation in the bone marrow of NOD mice is due  to homing Figure 2
T cell accumulation in the bone marrow of NOD 
mice is due to homing. A. Comparison of steady-state 
level of CD4 T cell proliferation in the bone marrow of 15–
16 week-old Balb/c and prediabetic NOD mice. Bone mar-
row cells were stained for TCR, CD4, CD44 and Ki67. Rep-
resentative Ki67 versus CD44 expression profiles are shown 
for TCR+CD4+ cells. The numbers are percentage of Ki67+ 
cells. B. Comparison of T cell homing to the bone marrow 
and lymph nodes in Balb/c and NOD mice. CFSE-labeled T 
cells from Balb/c or NOD mice were injected intravenously 
into both Balb/c and NOD recipients (12–16 week-old) and 
analyzed 2 hours following the transfer. Homing index is cal-
culated by dividing percentage of CFSE-positive donor CD4 
T cells in the bone marrow or lymph nodes by that in the 
spleen of the same recipient. Mean ± SD of homing index of 
CD4 T cells in at least four mice per group is shown. *p < 
0.01.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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Elevated CXCL12 expression correlates with T cell accumulation in the bone marrow of NOD mice Figure 3
Elevated CXCL12 expression correlates with T cell accumulation in the bone marrow of NOD mice. A. Analysis 
of chemokine expression in the bone marrow. RNA was isolated from bone marrow of Balb/c (n = 5) and prediabetic NOD (n 
= 6) mice, pooled, labeled and used as a probe to hybridize with GEArray chemokine array filters. Representative chemilumi-
nescent images from the hybridization are shown. 1, CCL19; 2, CXCL12. B. Quantitation of CXCL12 and CCL19 transcripts 
by RT-PCR. The same RNA as in A was used in real-time RT-PCR analysis for CXCL12, CCL19 and GAPDH. The relative 
transcript levels of CXCL12 and CCL19 to GAPDH are shown. C. Comparison of CXCL12 transcript levels in the bone mar-
row between 4–5 week-old NOD mice (n = 8) and Balb/c mice (n = 6). D. Comparison of CXCL12 transcript levels in the 
bone marrow among 6–9 week-old Balb/c (n = 5), EA16 (n = 3) and NOD (n = 8) mice. E. CXCR4 expression by CD4 T cells 
in different organs of Balb/c and prediabetic NOD mice. Cells from BM, LN and SP of Balb/c and prediabetic NOD mice were 
stained for TCR, CD4, CD45RB and CXCR4. Representative CXCR4 versus CD45RB profiles are shown for TCR+CD4+ cells. 
The numbers indicate percentages of cells in the gated areas. * p < 0.05.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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Interference of CXCR4 function delays the development of 
diabetes in NOD mice
To determine the relationship between CXCL12-mediated
dysregulation of T cell and stem cell trafficking and devel-
opment of diabetes, we treated NOD mice with AMD3100
and monitored progression of the disease. As shown in
Figure 6A, prediabetic NOD mice had significantly more
insulin-expressing islets than diabetic NOD mice (26.7 ±
5.2 per section versus 15.8 ± 9.4 per section, p < 0.05).
Among age-matched prediabetic NOD mice, AMD3100
treatment (daily for 8 days) significantly reduced lym-
phocyte infiltration into the islets (insulitis) (Figure 6A
and 6B). When prediabetic NOD mice (15–16 weeks of
age) were given AMD3100 or PBS daily for three weeks,
PBS-treated NOD mice rapidly developed diabetes
between 17 and 20 weeks of age as indicated by glucose
levels in the urine (>500 mg/dl) (Figure 6C). In contrast,
none of the AMD3100-treated mice developed glycosuria
disease during the same period. However, two weeks after
AMD3100 treatment was terminated, AMD3100-treated
mice began to develop diabetes and the incidence reached
the same level (70%) as PBS-treated mice by 26 weeks of
age. To test whether continuous AMD3100 treatment can
inhibit the development of diabetes, prediabetic NOD
mice (15 weeks of age) were given AMD3100 daily for 14
weeks. PBS-treated NOD mice started to show evidence of
diabetes at 16 weeks of age and by 29 weeks of age, all
mice developed diabetes (Figure 6D). In contrast, none of
the AMD3100-treated mice developed the disease during
AMD3100 inhibits naive T cell accumulation in the bone mar- row of NOD mice Figure 4
AMD3100 inhibits naive T cell accumulation in the 
bone marrow of NOD mice. Prediabetic NOD mice (15–
16 weeks of age) were treated with PBS or AMD3100 
(AMD) daily for 8 days. Two hr after the last AMD3100 
injection, mice were analyzed by flow cytometry. A, Compar-
ison of percentage of CD4 and CD8 T cells (mean ± SD) in 
the bone marrow of AMD3100 (n = 4) and PBS (n = 6) 
treated NOD mice. * p < 0.05. B, Comparison of CD44 ver-
sus CD45RB profiles of TCR+CD4+ cells from AMD3100 (n 
= 4) and PBS (n = 6) treated NOD mice. The numbers indi-
cate percentages of cells in the gated areas. The percentages 
(mean ± SE) of CD45RBhi CD44lo naïve T cells are 47.3 ± 
10.9 for PBS-treated mice and 24.8 ± 3.2 for AMD3100-
treated mice (p < 0.01).
The elevated CXCL12 expression promotes recruitment/retention of Treg and hematopoietic stem cells in the bone marrow Figure 5
The elevated CXCL12 expression promotes recruitment/retention of Treg and hematopoietic stem cells in 
the bone marrow. A. Comparison of the percentages and numbers of Foxp3+CD4+ Tregs in the bone marrow between age-
matched Balb/c (n = 7) and prediabetic NOD (n = 20) mice (15 weeks of age). Bone marrow cells were assayed for TCR, CD4 
and Foxp3. Tregs are identified as TCR+Foxp3+CD4+ cells. The percentage value of Foxp3+ cells is expressed as percent of 
CD4+ T cells. B. Effect of CXCR4 deletion on Treg distribution in the spleen and bone marrow. Cells from spleen and bone 
marrow of Cxcr4f/f Lck-Cre (KO) mice and littermate Cxcr4+/f Lck-Cre (WT) (8 weeks of age) were assayed for TCR, CD4, 
CD25 and Foxp3. The numbers of TCR+CD4+CD25+Foxp3+ cells are compared in the spleen and bone marrow from 3 mice 
per group. C. Comparison of numbers of hematopoietic stem cells (Lin-Sca1+c-Kit+, LSK) among age-matched Balb/c (n = 5), 
prediabetic NOD (n = 5) and AMD3100-treated (8 days) prediabetic NOD mice (n = 4). *p < 0.05.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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AMD3100 treatment inhibits leukocyte infiltration and development of diabetes in NOD mice Figure 6
AMD3100 treatment inhibits leukocyte infiltration and development of diabetes in NOD mice. A. Immunohisto-
logical staining of pancreatic sections of NOD mice. The pancreas of prediabetic, diabetic NOD mice or prediabetic NOD 
mice that have been given AMD3100 for 8 days were fixed and embedded. Parallel tissue sections were stained with haematox-
ylin and eosin (H&E, top panel), anti-glucagon (middle panel) or anti-insulin (bottom panel) antibodies. Note lymphocyte infil-
tration in the islets of prediabetic NOD mouse without AMD3100 treatment. B. Percentage of insulitis in pancreatic sections 
of 15 week-old prediabetic NOD mice that were given daily with PBS (n = 8) or AMD3100 (n = 6) for 8 days. *p < 0.01. C and 
D. Comparison of diabetes incidence in NOD mice that were given AMD3100 or PBS for 3 weeks (C) or 14 weeks (D), start-
ing at 15–16 weeks of age. Number of mice in each group (n) is shown. Mice are scored as diabetic when glucose level in the 
urine reaches 500 mg/dl. p < 0.01.BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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the same period. These results show that AMD3100 treat-
ment inhibits leukocyte infiltration in the islets (insulitis)
and continuous treatment delays development of overt
diabetes.
Discussion
We show here that among all chemokines examined the
level of CXCL12 transcript, which is tightly correlated
with the protein level [14], is significantly elevated in the
bone marrow of NOD mice as compared to Balb/c mice.
CXCL12 specifically stimulates chemotaxis of cells that
express CXCR4 [20,22,23]. The elevated CXCL12 levels
are therefore expected to have a significant effect on
recruitment and retention of CXCR4-expressing cells in
the bone marrow of NOD mice. Based on analyses of
young, prediabetic, diabetic NOD mice and EA16 mice,
the phenotype of CXCR4-expressing T cells, the effect of
AMD3100 treatment, and direct recruitment assay, our
studies unequivocally demonstrate that the elevated
CXCL12 expression results in recruitment and accumula-
tion of naïve T cells in the bone marrow of NOD mice.
Because there is no difference in the proportion of T cells
that express CXCR4 between NOD and Balb/c mice, and
because Balb/c T cells are also preferentially recruited to
the NOD bone marrow, the observed recruitment and
accumulation of naïve T cells in the bone marrow of NOD
mice appears to be due solely to the elevated CXCL12
expression. In addition, our results show that the elevated
CXCL12 expression also leads to the accumulation/reten-
tion of Tregs and HSC in the bone marrow.
What is the relationship between the elevated CXCL12
expression in the bone marrow and development of dia-
betes in NOD mice? The elevated CXCL12 expression is
unlikely a consequence of inflammation or hyperglyc-
emia associated with insulitis or diabetes in NOD mice
because CXCL12 transcript was detected in the bone mar-
row of EA16 mice and young (4–5 week old) NOD mice.
More likely, NOD mice are predisposed to express ele-
vated CXCL12 in the bone marrow. Conversely, because
EA16 mice do not develop diabetes despite the elevated
CXCL12 expression and accumulation of T cells in the
bone marrow, the elevated CXCL12 expression alone is
insufficient to initiate diabetes in the absence of autoreac-
tive T cells. Nevertheless, the elevated CXCL12 expression
likely promotes diabetes development. In humans, poly-
morphisms in CXCL12 gene are linked to susceptibility to
TID [10-12]. Using allele-specific transcript quantification
in Epstein-Barr virus-transformed lymphoblastoid cell
lines, one study reported evidence that polymorphisms
have a cis-acting effect on CXCL12 transcription [24].
However, whether TID patients with specific CXCL12 pol-
ymorphisms have elevated CXCL12 expression has not
been reported. In NOD mice, neutralization of CXCL12
by administration of antibody suppresses insulitis and
delays the onset of diabetes [15]. Similarly, administra-
tion of G-CSF, a cytokine known to induce suppression of
CXCL12 transcription, also reduces insulitis and diabetes
in NOD mice [15,16]. Consistent with these previous
observations, we found that the elevated CXCL12 expres-
sion and its consequent effect on T cell trafficking are pos-
itively correlated with the disease progression in NOD
mice. Complete Freund adjuvant (CFA), which is known
to inhibit diabetes development [25,26], also inhibits
CXCL12 expression [27] and T cell accumulation in the
bone marrow of NOD mice (see Additional file 3).
Finally, treatment of prediabetic NOD mice with
AMD3100 abolishes T cell accumulation in the bone mar-
row and simultaneously inhibits disease development.
Together, these findings strongly suggest that CXCL12
promotes development of diabetes in NOD mice and per-
haps in humans.
Our findings also suggest potential mechanisms by which
the elevated CXCL12 expression promotes disease pro-
gression in NOD mice. We found that the elevated
CXCL12 expression leads to homing of naïve T cells to the
bone marrow. A recent study showed that diabetogenic T
cells also preferentially home to the bone marrow of NOD
mice [28], perhaps as a result of the elevated CXCL12
expression shown here. It is possible that accumulation of
T cells in the bone marrow of NOD mice might lead to
lymphopenia in the peripheral lymphoid organs and
homeostatic proliferation and differentiation of autoreac-
tive T cells [29-32], which in turn promotes diabetes
development. It is also possible that elevated CXCL12
expression may promote disease progression in NOD
mice through its effect on trafficking of autoreactive T
cells, especially into islets. Studies have shown that
CXCL12-CXCR4 interaction is required for recruitment of
autoreactive T cells to rheumatoid arthritis synovium and
the inflamed joint of collagen-induced arthritis [33,34].
In a virus-induced TID model, blockade of CXCL10 (IP-
10) prevents diabetes development by impeding expan-
sion of autoreactive T cells and their migration into the
pancreas [35]. We showed that inhibition of CXCR4 by
AMD3100 significantly reduced insulitis (Figure 5B).
Although we did not detect any difference in CXCL12
expression in pancreas between prediabetic NOD mice
and BALB/c mice (data not shown), dysregulation of lym-
phocyte trafficking is likely a significant contributing fac-
tor to the development of TID in NOD.
The elevated CXCL12 expression may promote disease
progression in NOD mice through its effect on Treg traf-
ficking, which is partly regulated by CXCL12-CXCR4
interaction. A large body of evidence suggests that Tregs
play a critical role in suppressing autoimmunity [36]. In
NOD mice, the frequency and function of Foxp3+ Tregs
were reported to decrease with age [37]. We show thatBMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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more Tregs were present in the bone marrow of NOD
mice than age-matched BALB/C mice. Following
AMD3100 treatment of NOD mice, the number of Tregs
was significantly decreased in the bone marrow whereas
the number was significantly increased in the spleen (see
Additional file 4). However, because the number of Tregs
in the bone marrow is only about one tenth of that in the
spleen, Treg mobilization from the bone marrow alone
cannot account for the significant increase in Treg num-
bers in the spleen. Regardless where the splenic Tregs
come from, because a threshold ratio of Tregs to autoreac-
tive T cells is important for Treg suppression of autoreac-
tive T cells [6,38], sequestering Tregs in the bone marrow
or some other organs in NOD mice may tip the balance in
favor of autoreactive T cells.
The elevated CXCL12 expression also leads to retention of
hematopoietic stem cells in the bone marrow of NOD
mice. Because bone marrow-derived stem cells initiate
pancreatic regeneration [39], it is possible that sequester-
ing HSC and possibly other stem/progenitor cells in the
bone marrow might contribute to disease progression in
NOD mice by limiting their availability for islet regenera-
tion. In support of this notion, systemic administration of
CXCL12 ameliorates diabetes [40], perhaps partly by
mobilizing HSC from the bone marrow to the periphery.
The same mechanism may partly explain the effectiveness
of CFA plus adoptive transfer of splenocytes, which con-
tain a significant number of HSC and probably other pro-
genitor cells [41], in curing diabetic NOD mice through
regeneration of islets [42-45].
AMD3100 was originally developed to treat HIV infection
through its antagonism of the CXCR4, a co-receptor for
the virus [17]. Currently, it is being developed as an agent
to mobilize HSC from bone marrow to peripheral blood
for transplantation of stem cells in patients with non-
Hodgkin's lymphoma or multiple myeloma [46]. We
found that AMD3100 treatment of prediabetic NOD mice
significantly delays insulitis and the onset of diabetes. In
contrast, a recent study reported that AMD3100 treatment
promotes diabetes development in a model where diabe-
tes was induced by adoptive transfer of splenocytes from
female NOD mice into sublethally irradiated male NOD
mice [47]. In the transfer model, transferred T cells
undergo homeostatic proliferation and acquire effector
functions [30-32]. Irradiation of the recipient mice also
introduces additional factors and processes which are not
active in the non-irradiated prediabetic mice. Thus, the
disease induction mechanisms in the transfer model
could be significantly different from those in un-manipu-
lated female NOD mice. Although the precise mechanism
underlying the discrepancy between the two studies has
yet to be determined, our finding provides a basis for fur-
ther exploring the use of AMD3100 to prevent and/or
treat TID and possibly other autoimmune diseases in
patients with elevated CXCL12 or CXCR4 expression.
Conclusion
Elevated CXCL12 expression in the bone marrow of NOD
mice likely promotes development of TID by altering T
cell and hematopoietic stem cell trafficking. The findings
suggest the possibility of preventing and/or treating TID
in humans by modulating either the expression or func-
tion of CXCL12 and CXCR4.
Methods
Mice
NOD mice from Taconic Farms were bred in our facilities.
Female NOD mice were used in all studies and monitored
for diabetes by checking the urine glucose level at least
two times per week, starting around 12 week of age. Mice
were considered diabetic when urinary glucose level
reached 500 mg/dl, as measured with Diastix (Bayer Diag-
nostics). In our facility, approximately 95% of untreated
NOD female mice became diabetic by 7-months of age.
Balb/c mice were purchased from the Jackson Laboratory.
EA16NOD mice were a gift from Drs. Diane Mathis and
Christopher Benoist. Cxcr4f/f Lck-Cre mice and littermate
Cxcr4+/f Lck-Cre were on the mixed 129/C57BL/6 back-
ground and were generated by breeding Cxcr4+/f Lck-Cre
mice. All mice were kept under specific pathogen free
facilities. For AMD3100 treatment, prediabetic NOD mice
were given AMD3100 (5 mg/kg) subcutaneously daily for
the indicated length of time. For analysis of T cell distribu-
tion, the mice were sacrificed after 2 hour of last
AMD3100 injection. All animal studies are approved by
the institutional Committees on Animal Care.
Antibodies and flow cytometry
Single-cell suspensions were prepared from the spleen,
lymph nodes and bone marrow. All staining antibodies
were purchased from BDbioscience, except anti-Foxp3,
lineage markers (Lin), and c-Kit and Sca-1, which were
from E-bioscience, Stem Cell Technologies, and Bioleg-
end, respectively. Cells were stained in the presence of 2.5
μg/ml anti-FcR antibody in PBS containing 0.1% BSA and
0.1% NaN3 and analyzed on a FACScaliber or a LSR II or
a FACSAria, collecting 10,000 to 1,000,000 live cells per
sample. Analyses were carried out with Flowjo software.
For analysis of LSK cells, 10% of total cells with low level
of lineage marker expression were gated for further analy-
sis of Sca-1 versus c-kit expression profile. Intracellular
staining of Foxp3 and Ki67 was performed according to
the manufacturer's instruction.
Immunohistochemistry
The pancreata were fixed in 10% formalin, embedded in
paraffin, and sectioned. Paraffin-embedded tissue sec-
tions were stained with haematoxylin and eosin, and par-BMC Immunology 2008, 9:51 http://www.biomedcentral.com/1471-2172/9/51
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allel sections were stained with polyclonal guinea pig anti-
insulin (Zymed) or anti-glucagon antibodies (Linco
Research Inc.), followed by incubation with ABC systems
Kit (Vector laboratories). For destructive insulitis (loss of
insulin staining), insulin-stained sections of pancreata
were matched to serial sections stained for glucagon. Insu-
litis is defined as presence of infiltrating lymphocytes in
islets regardless whether they stained positive for insulin
or not.
Chemokine gene expression
RNA was isolated from bone marrow using Trizol (Invit-
rogen), reverse transcribed using the Ampho-Labeling kit
(Superarray, Frederick, MD), and the cDNA was labeled
with biotin-16-dUTP (Roche). Cytokine expression was
assessed using an Oligo GEArray® Mouse Chemokines &
Receptors Microarray (Superarray, Frederick, MD). Real-
time PCR for CXCL12, CCL19, and GAPDH transcripts
was performed with the probes and master mixture kit
from Applied Biosystems.
Homing of T cells
T cells were purified from lymph nodes and spleens from
12–16 week old NOD and Balb/c mice by negative deple-
tion using a MACS and staining with biotinylated anti-
bodies specific for CD11b, CD11c and B200 and
subsequently with streptavidin-microbeads. The purified
T cells (> 95% purity) were labeled with 1.5 μM CFSE,
washed and then suspended in HBSS solution. 20 or 50 ×
106 CFSE-labeled cells were transferred into the NOD and
Balb/c mice. After 2 hr (for mice transferred with 50 × 106
cells) or 48 hr (for mice transferred with 20 × 106 cells)
recipients were sacrificed, and the frequency of transferred
CD4 T cells was determined in the bone marrow, lymph
nodes and spleen by flow cytometry assaying for CFSE
and CD4. To correct for differences in the input cell num-
bers among individual recipient mice, the homing index
(HI) was calculated: HI = [% CFSE+ CD4 T cells in BM or
LN]/[% CFSE+ CD4 T cells in spleen].
Statistics
Statistical analysis for significance was done with either a
two-tailed Student's t-test or a Kaplan-Meier product limit
estimation. Error bars shown in all figures are one stand-
ard deviation.
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